A.I. Virtanen -instituutti
A.I. Virtanen Institute for Molecular Sciences

Julkaisut 1996
Publications 1996

Lisätietoja julkaisusta saa klikkaamalla sen numeroa.
For full details, please click the number in front of the publication.


1 Ala-Korpela M et al. Absolute quantification of phospholipid metabolites in brain-tissue extracts by 1H NMR spectroscopy.
2 Alhonen L et al. Transgenic mice expressing the human ornithine decarboxylase gene under the control of mouse metallothionein I promoter.
3 Alhonen L et al., ed. The First Annual A.I.Virtanen Institute Post-Graduate Mini-Symposium 1996. 1st March, 1996, Kuopio, Finland. Abstracts.
4 Björklund M et al. Alpha2c-adrenoceptor overexpressing mice as a model to study cognitive functions of alpha2-adrenoceptors.
5 Diez M et al. Aberrant induction of neuropeptide Y mRNA in hippocampal CA3 pyramidal neurones in scrapie-infected mice.
6 European Carotid Surgery Trialists` Collaborative Group. Endarterectomy for moderate symptomatic carotid stenosis: interim results from the MRC european carotid surgery trial.
7 Galuske RAW et al. Brain-derived neurotrophic factor reverses experience-dependent synaptic modifications in kitten visual cortex.
8 Gröhn O, Kauppinen R. Intracellular chelation of calcium prevents cell damage following severe hypoxia in the rat cerebral cortex as studied by NMR spectroscopy ex vivo.
9 Hakkarainen M et al. Hypermethylation of calcitonin gene regulatory sequences in human breast cancer as revealed by genomic sequencing.
10 Hakumäki JM et al. Increased macromolecular resonances in the rat cerebral cortex during severe energy failure as detected by 1H nuclear magnetic resonance spectroscopy.
11 Halonen T et al. Tiagabine prevents seizures, neuronal damage and memory impairment in experimental status epilepticus.
12 Heitzer T et al. Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia. Role of oxidized LDL.
13 Helisalmi S et al. Apolipoprotein E polymorphism in patients with different neurodegenerative disorders.
14 Helisalmi S et al. Screening for amyloid beta precursor protein codon 665, 670/671 and 717 mutations in Finnish patients with Alzheimer's disease.
15 Helkala E-L et al. Slow-wave activity in the spectral analysis of the electroencephalogram and volumes of hippocampus in subgroups of Alzheimer`s disease patiens.
16 Helkala E-L et al. Memory functions in human subjects with different apolipoprotein E phenotypes during a 3-year population-based follow-up study.
17 Hyttinen J-M. Transgenic Farm Animals as Bioreactors.
18 Hyttinen J-M et al. Detection of microinjected genes in bovine preimplantation embryos with combined DNA digestion and polymerase chain reaction.
19 Hyttinen JMT. Chlorinated Hydroxyfuranones. Studies on Their Mutagenicity and Molecular Mechanism of Action.
20 Hyttinen JMT et al. Kinds of mutations induced by 3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone (MX) in the hprt gene of Chinese hamster ovary cells.
21 Hänninen T et al. Prevalence of ageing-associated cognitive decline in an elderly population.
22 Jolkkonen J et al. Seizure-induced damage to the hippocampus is prevented by modulation of the GABAergic system.
23 Jänne J et al. Genetic engineering of polyamine metabolism in transgenic rodents.
24 Karhunen LJ et al. Determinants of the cephalic-phase insulin response in obese nondiabetic subjects.
25 Koikkalainen M et al. Why cardiac patients do not follow the nutritionist's advice: barriers in nutritional advice perceived in rehabilitation.
26 Koistinaho J et al. Long-term induction of haem oxygenase-1 (HSP-32) in astrocytes and microglia following transient focal brain ischaemia in the rat.
27 Koistinaho J et al. Expression of beta-amyloid precursor protein mRNAs following transient focal ischaemia.
28 Kosunen O et al. Diagnostic accuracy of Alzheimer's disease: a neuropathological study.
29 Kotti T et al. The calretinin-containing mossy cells survive excitotoxic insult in the gerbil dentate gyrus. Comparison of excitotoxicity-induced neuropathological changes in the gerbil and rat.
30 Kälviäinen R, Riekkinen PJ Sr. In reply (to Vigabatrin and carbamazepine monotherapy for newly diagnosed epilepsy).
31 Kälviäinen R et al. Long-term cognitive and EEG effects of tiagabine in drug-resistant partial epilepsy.
32 Kälviäinen R et al. Cognitive adverse effects of antiepileptic drugs. Incidence, mechanisms and therapeutic implications.
33 Laakso MP et al. MR T2 relaxometry in Alzheimer's disease and age-associated memory impairment.
34 Lahtinen H et al. Failure of carbamazepine to prevent behavioural and histopathological sequels of experimentally induced status epilepticus.
35 Lehtovirta M et al. Spectral analysis of EEG in Alzheimer's disease: relation to apolipoprotein E polymorphism.
36 Lehtovirta M et al. Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease: relation to apolipoprotein E polymorphism.
37 Lehtovirta M et al. SPECT and MRI analysis in Alzheimer's disease: relation to apolipoprotein E epsilon4 allele.
38 Luoma J, Ylä-Herttuala S. Atherosclerosis in Watanabe heritable hyperlipidemic rabbit arteries.
39 Marty S et al. Brain-derived neurotrophic factor promotes the differentiation of various hippocampal nonpyramidal neurons, including Cajal-Retzius cells, in organotypic slice cultures.
40 Mato M et al. Involvement of specific macrophage-lineage cells surrounding aterioles in barrier and scavenger function in brain cortex.
41 Miettinen M et al. Coexistence of parvalbumin and GABA in nonpyramidal neurons of the rat entorhinal cortex.
42 Miettinen S et al. Specific induction of protein kinase Cdelta subspecies after transient middle cerebral artery occlusion in the rat brain: inhibition by MK-801.
43 Partanen J et al. EEG reactivity correlates with neuropsychological test scores in Down's syndrome.
44 Petit D et al. Electrophysiological tests.
45 Pirttilä T et al. Cerebrospinal fluid concentrations of soluble amyloid beta-protein and apolipoprotein E in patients with Alzheimer's disease.
46 Pirttilä T et al. Apolipoprotein E (apoE) levels in brains from Alzheimer disease patients and controls.
47 Pitkänen A. Treatment with antiepileptic drugs: Possible neuroprotective effects.
48 Pitkänen A et al. Severity of hippocampal atrophy correlates with the prolongation of MRI T2 relaxation time in temporal lobe epilepsy but not in Alzheimer's disease.
49 Pitkänen A et al. Vigabatrin and carbamazepine have different efficacies in the prevention of status epilepticus induced neuronal damage in the hippocampus and amygdala.
50 Puumala T et al. Behavioral and pharmacological studies on the validation of a new animal model for attention deficit hyperactivity disorder.
51 Puumala T et al. Effects of St-587 and prazosin on water maze and passive avoidance performance of scopolamine-treated rats.
52 Reeben M et al. Induced expression of neurotrophins in transgenic mice overexpressing ornithine decarboxylase and overproducing putrescine.
53 Reeben M et al. The effects of noradrenergic lesion and alfa2-adrenergic drugs on nerve growth factor and brain-derived neurotrophic factor mRNA expression in the rat hippocampus and peripheral tissues.
54 Riekkinen PJ Sr et al. Rationale to treat Alzheimer's disease with selegiline - can we prevent the progression of the disease?
55 Roivainen R, Koistinaho J. Histochemical detection of age- and injury-related changes in signal transduction in the superior cervical ganglion.
56 Salmenperä T et al. Cost of epilepsy: review of the literature.
57 Savander V et al. Intrinsic connections of the rat amygdaloid complex: projections originating in the accessory basal nucleus.
58 Savander V et al. Topographic projections from the periamygdaloid cortex to select subregions of the lateral nucleus of the amygdala in the rat.
59 Sipiläinen R et al. Rasvamieltymykset laihdutuksen aikana.
60 Sirviö J et al. Animal models of attention deficit hyperactivity disorder (ADHD).
61 Soininen HS et al. ApoE genotype and MRI volumetry: implication for therapy.
62 Soininen HS, Riekkinen PJ Sr. Apolipoprotein E, memory and Alzheimer's disease.
63 Sorvari H et al. Parvalbumin-immunoreactive neurons make inhibitory synapses on pyramidal cells in the human amygdala: a light and electron microscopic study.
64 Sorvari H et al. Calretinin-immunoreactive cells and fibers in the human amygdaloid complex.
65 Sorvari H et al. Calbindin-D28K-immunoreactive cells and fibres in the human amygdaloid complex.
66 Tolvanen M et al. Siirtogeeniset eläimet.
67 Tuomisto MT et al. Korkeakouluopiskelijoiden ravintokäyttäytyminen, paino ja niihin suhtautuminen.
68 Tuomisto MT et al. Sovellettu rentoutus hoitomenetelmänä psykiatriassa ja käyttäytymislääketieteessä.
69 Tuomisto T et al. Syömisen taito: psykologisia selityksiä painon hallintaan.
70 Tuunanen J et al. Status epilepticus causes selective regional damage and loss of GABAergic neurons in the rat amygdaloid complex.
71 Usenius J-P et al. Automated classification of human brain tumours by neural network analysis using in vivo 1H magnetic resonance spectroscopic metabolite phenotypes.
72 Usenius T et al. Ionizing radiation induces expression of immediate early genes in the rat brain.
73 Uusitupa MIJ et al. Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus.
74 Vanhanen M et al. ERPs reveal deficits in automatic cerebral stimulus processing in patients with NIDDM.
75 Vartiainen N et al. Induction of thymosin beta4 mRNA following focal brain ischemia.
76 Witkin JM et al. Behavioral and biochemical characterization of benzodiazepine receptor partial agonists in pigeons.
77 Wong G et al. Effects of clozapine metabolites and chronic clozapine treatment on rat brain GABAA receptors.
78 Wong G et al. Brain regional pharmacology of GABAA receptors in alcohol-preferring AA and alcohol-avoiding ANA rats.
79 Wong G et al. Pharmacologic actions of subtype-selective and novel GABAergic ligands in rat lines with differential sensitivity to ethanol.
80 Yavich L et al. The systemic administration of tacrine or selegiline facilitate spatial learning in aged fisher 344 rats.
81 Ylä-Herttuala S. Oksidoituneet lipoproteiinit ja valtimonkovettumatauti.
82 Ylä-Herttuala S. Gene therapy for cardiovascular diseases.
83 Ylä-Herttuala S. Expression of lipoprotein receptors and related molecules in atherosclerotic lesions.
84 Ylä-Herttuala S. LDL oxidation and atherogenesis.
85 Ylä-Herttuala S et al. Pathogenesis of atherosclerosis.
86 Ylä-Herttuala S et al. Ihmisen geeniterapia.

A.I. Virtanen -instituutti A.I. Virtanen Institute for Molecular Sciences
Julkaisutietokanta 15.4.2008 Publications Data Base 15.4.2008